Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
17.34 USD | -1.00% |
|
-0.03% | -5.97% |
Voraussichtliche Gewinn- und Verlustrechnung: ACADIA Pharmaceuticals Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Umsatz 1 | 339.1 | 441.8 | 484.1 | 517.2 | 726.4 | 974.5 | 1’057 | 1’157 |
Veränderung | - | 30.28% | 9.6% | 6.83% | 40.45% | 34.14% | 8.45% | 9.52% |
EBITDA 1 | -243.8 | -283.7 | -167.1 | -221.6 | -67.83 | 123.8 | 124 | 217.7 |
Veränderung | - | 16.36% | -41.09% | 32.6% | -69.39% | - | 0.18% | 75.6% |
Betriebsergebnis (EBIT) 1 | -246.5 | -286.6 | -170.4 | -223.6 | -73.38 | 113.6 | 123.1 | 197.7 |
Veränderung | - | 16.24% | -40.53% | 31.19% | -67.18% | - | 8.29% | 60.63% |
Gezahlte Zinsen | - | - | - | - | - | - | - | - |
Gewinn vor Steuern (EBT) 1 | -234.4 | -281 | -167.5 | -213.4 | -51.04 | 137 | 136.8 | 228.2 |
Veränderung | - | 19.88% | -40.38% | 27.41% | -76.09% | - | -0.21% | 66.9% |
Nettoergebnis 1 | -235.3 | -281.6 | -167.9 | -216 | -61.29 | 120.3 | 138.5 | 210.6 |
Veränderung | - | 19.69% | -40.38% | 28.66% | -71.62% | - | 15.15% | 52.01% |
Datum der Veröffentlichung | 26.02.20 | 24.02.21 | 28.02.22 | 27.02.23 | 27.02.24 | - | - | - |
Vorläufige Bilanz: ACADIA Pharmaceuticals Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoverschuldung 1 | -697 | -632 | -521 | -417 | -439 | -608 | -826 | -1’059 |
Veränderung | - | -190.67% | -182.44% | -180.04% | -205.28% | -238.54% | -235.86% | -228.21% |
Datum der Veröffentlichung | 26.02.20 | 24.02.21 | 28.02.22 | 27.02.23 | 27.02.24 | - | - | - |
Prognostizierter Cashflow: ACADIA Pharmaceuticals Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX Investitionsaufwand 1 | 1.129 | 7.587 | 1.122 | - | 0.05 | 3.655 | 3.447 | 2.54 |
Veränderung | - | 572.01% | -85.21% | - | - | 7’209.8% | -5.7% | -26.29% |
Free Cashflow (FCF) 1 | -152.3 | -143.8 | -126.8 | -114 | 16.65 | 156.5 | 161.9 | 202.7 |
Veränderung | - | -5.59% | -11.81% | -10.05% | -114.6% | 839.83% | 3.48% | 25.14% |
Datum der Veröffentlichung | 26.02.20 | 24.02.21 | 28.02.22 | 27.02.23 | 27.02.24 | - | - | - |
Voraussichtliche Finanzkennzahlen: ACADIA Pharmaceuticals Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Rentabilität | ||||||||
EBITDA-Marge (%) | -71.9% | -64.21% | -34.51% | -42.84% | -9.34% | 12.7% | 11.73% | 18.81% |
EBIT-Marge (%) | -72.71% | -64.87% | -35.2% | -43.23% | -10.1% | 11.66% | 11.64% | 17.08% |
EBT-Marge (%) | -69.12% | -63.6% | -34.6% | -41.27% | -7.03% | 14.06% | 12.94% | 19.72% |
Nettogewinn (%) | -69.38% | -63.74% | -34.67% | -41.76% | -8.44% | 12.35% | 13.11% | 18.2% |
FCF-Marge N (%) | -44.9% | -32.54% | -26.19% | -22.05% | 2.29% | 16.06% | 15.32% | 17.51% |
FCF / Nettogewinn (%) | 64.72% | 51.05% | 75.52% | 52.8% | -27.17% | 130.07% | 116.89% | 96.23% |
Rentabilität | ||||||||
ROA | -35.55% | -35.97% | -22.64% | -33.54% | -9.17% | 18.48% | 15.7% | 15.52% |
ROE | -39.93% | -42.47% | -28.75% | -45.89% | -14.73% | 20.16% | 21.27% | 18.89% |
Finanzielle Gesundheit | ||||||||
Verschuldungsgrad (Verbindlichkeiten/EBITDA) | - | - | - | - | - | - | - | - |
Verschuldung / Free Cashflow | - | - | - | - | - | - | - | - |
Kapitalintensität | ||||||||
CAPEX / Umsatz (%) | 0.33% | 1.72% | 0.23% | - | 0.01% | 0.38% | 0.33% | 0.22% |
CAPEX / EBITDA (%) | -0.46% | -2.67% | -0.67% | - | -0.07% | 2.95% | 2.78% | 1.17% |
CAPEX / FCF (%) | -0.74% | -5.28% | -0.88% | - | 0.3% | 2.34% | 2.13% | 1.25% |
Elemente pro Aktie | ||||||||
Cashflow pro Aktie 1 | -1.027 | -0.8655 | -0.783 | -0.7053 | 0.102 | 0.934 | 1.118 | 1.55 |
Veränderung | - | -15.7% | -9.53% | -9.92% | -114.46% | 815.69% | 19.7% | 38.64% |
Dividende pro Aktie 1 | - | - | - | - | - | - | - | - |
Veränderung | - | - | - | - | - | - | - | - |
Buchwert je Aktie 1 | 4.503 | 3.928 | 3.359 | 2.471 | 2.636 | 3.757 | 5.128 | 6.621 |
Veränderung | - | -12.77% | -14.47% | -26.45% | 6.67% | 42.54% | 36.5% | 29.11% |
Gewinn pro Aktie 1 | -1.6 | -1.79 | -1.05 | -1.34 | -0.37 | 0.6795 | 0.7696 | 1.12 |
Veränderung | - | 11.87% | -41.34% | 27.62% | -72.39% | -283.64% | 13.27% | 45.55% |
Anz. der Aktien (in Tausend) | 154’025 | 158’978 | 160’756 | 161’931 | 164’180 | 166’392 | 166’392 | 166’392 |
Datum der Veröffentlichung | 26.02.20 | 24.02.21 | 28.02.22 | 27.02.23 | 27.02.24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
KGV | 25.8x | 22.8x |
KBV | 4.66x | 3.41x |
EV / Sales | 2.37x | 1.98x |
Rendite | - | - |
Gewinn pro Aktie & Dividende
Historische Entwicklung KGV
Entwicklung der Dividendenrendite
![Analystenschätzungen](https://cdn.zonebourse.com/images/consensus_flch.gif)
Quartalsumsätze - Abweichungsrate
- Börse
- Aktien
- 603035 Aktie
- Finanzen ACADIA Pharmaceuticals Inc.
![Vereinigte Staaten](/images/png-country/24x24/us.png)
MarketScreener is also available in this country: United States.
Switch edition